SDpress April 2016

Innovation That Matters

Placing ‘Early’ Bets in Biotech – A Chat With Andy Schwab, Co-Founder & Managing Partner, 5AM Ventures

Next Generation Immuno-Oncology: Creating a New Pathway to ‘Eat’ Cancer – A Chat with Jonathan MacQuitty, CEO, Forty Seven

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David 

Connecting the Global Autism Scientific Community – A Chat With Alan Packer, Senior Scientist, Simons Foundation Autism Research Initiative

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

WuXi News

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia

WuXi Acquires Crelux

Juno Therapeutics and WuXi Start New Company to Develop Novel Cell-Based Cancer Immunotherapies in China

WuXi Lab Testing Division’s Analytical and Stability Testing Facilities Passed FDA Inspection

WuXi Opens Office in South Korea

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

Webinar: Tackling #1 Drug Development Problem: Solubility (May 5)

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

WuXi’s STA Subsidiary Opens New Campus in Changzhou
In This Issue
Industry Beats

Top 10 San Diego Deals in Q1 (Source: Xconomy) 

Study Links Coffee Consumption to Decreased Risk of Colorectal Cancer (Source: USC)

Human Longevity Announces 10 Year Deal with AstraZeneca to Sequence and Analyze Patient Samples from AstraZeneca Clinical Trials (Source: Human Longevity)

Zavante Therapeutics Closes $45M Series A Financing in Support of U.S. Development for a First-in-class Injectable Antibiotic (Source: Zavante)

Human Longevity Completes $220M Series B Financing (Source: Human Longevity) 

EnsoData Raises $550K to Develop Software That Analyzes Sleep Data (Source: Xconomy)

RiverVest Venture Partners Opens San Diego Office That’s Been 10 Years in the Making (Source: RiverVest)

UCSD Scientist Named to Panel Advising Biden on Cancer ‘Moonshot’ (Source: UCSD)

Drug Approvals and Designations

Upcoming Events

April 28, 2016
LA BioMed, Torrance
 
April 29, 2016
Salk Institute, La Jolla
 
May 2, 2016
Biocom, San Diego
 
May 17, 2016
OCTANe, Orange Country
 
May 25, 2016
Biocom, San Diego
Follow us on TwitterView our profile on LinkedIn

BAYpress March 2016

WuXi Global Webinar “Pioneering Approaches to Dismantling Cancer”


 
Wednesday, April 6, 2016 (10AM-11AM PST)
Speakers include:
 
James Audia, CSO, Constellation Pharmaceuticals
Philip Gotwals, Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of BioMedical Research
Jason Rhodes, Partner, Atlas Venture
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (moderator)

Click here to register

Around Town

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David

WuXi Spring Reception in San Francisco

Innovation That Matters

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

WuXi Releases New Mobile App for Compound Sourcing

WuXi Opens Office in South Korea

WuXi’s STA Subsidiary Opens New Campus in Changzhou

In This Issue
Industry Beats

Takeda and Frazier Healthcare Partners Launch Outpost Medicine to Develop New Therapeutics in Urology and Gynecology (Outpost Medicine)Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the U.S., Canada, and Japan (Source: Exelixis)

Startup Arterys Emerges with Diagnostic Technology (Source: WSJ)

23andMe Enables Genetic Research for ResearchKit Apps (Source: 23andMe)

Kite Pharma Enters Clinical Trial Collaboration with Genentech to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma (Source: Kite Pharma)

BioMarin Heads to FDA with Mixed Data For Rare Disease Drug (Source: Xconomy)

Dr. Reddy’s Buys U.S Rights to XenoPort’s Psoriasis Drug (Source: XenoPort)

Third Rock Ventures Launches Pliant Therapeutics with $45M Series A to Treat Fibrotic Diseases (Source: Pliant)

Stanford Spins Out Immunotherapy Work Funded by CIRM’s Millions (Source: Xconomy)

Google Ventures Leads $21M Series B for Epigenetic Sequencing Startup, as it Adds Ex-Illumina Exec as CEO (Source: FierceMedicalDevices)

Tizona Therapeutics Completes $43M Series B Financing (Source: Tizona)

Rani Therapeutics Completes Latest Round of Funding; Brings Total Investment to $70M (Source: Rani Therapeutics)

10x Genomics Completes $55M Series C Financing (Source: 10x Genomics)

Corvus Pharmaceuticals Announces Pricing of IPO (Source: Corvus)

HealthTell Completes A $26M Series B Financing (Source: BioSpace)

Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform (Source: Sanofi)

Caribou Bio’s New CRISPR Patent Isn’t About Gene Editing (Source: Xconomy)

FDA Drug Approvals & Designations

Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection (Source: Merck)

Upcoming Events

April 7, 2016
CLSA, Meno Park
April 14-15, 2016
Biotech Primer, South San Francisco
April 16-20, 2016
AACR, New Orleans
Visit us at booth #1756
 
June 6-9, 2016
BIO, San Francisco
Follow us on Twitter

MApress Newsletter March 2016

WuXi Global Webinar “Pioneering Approaches to Dismantling Cancer”


 
Wednesday, April 6, 2016 (10AM PST | 1PM EST | 6PM GMT)
Cancer continues to be a leading cause of morbidity and mortality worldwide with more than 8 million deaths and 14 million new cases per year.  Significant advances have been made to unravel cancer’s mysteries and complexities at the genetic-, molecular- and pathway-levels. They not only reveal new scientific insights into the biology of diseases, but also herald a new era with fresh perspectives for the prevention, diagnosis, and more effective, precision-driven therapies.  In this complimentary live webinar open to life science professionals globally, WuXi brings together scientific and executive leaders from pharma, biotech and the venture capital community to discuss “Pioneering Approaches to Dismantling Cancer.”
Our distinguished speakers include:
 
James Audia, CSO, Constellation Pharmaceuticals
Philip Gotwals, Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of BioMedical Research
Jason Rhodes, Partner, Atlas Venture
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (moderator)

Click here to register

Local Perspectives

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

Innovation That Matters

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia

WuXi Opens Office in South Korea

WuXi Spring Reception in San Francisco

Over 1,100 Executives Signed-up for 4th Annual WuXi Global Forum at J.P. Morgan Conference

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

WuXi Releases New Mobile App for Compound Sourcing

WuXi’s STA Subsidiary Opens New Campus in Changzhou

WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
In This Issue
Industry Beats

Sage Therapeutics to Present SAGE-547 Clinical Data and SRSE Health Economic Data in Five Abstracts at the American Academy of Neurology 2016 Annual Meeting (Source: Sage Therapeutics)WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018 (Source: WAVE Life Sciences)

First Four Biotech Startups of 2016 Begin MassCONNECT Program (Source: Boston Business Journal)

Allied-Bristol Life Sciences Launches iβeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway (Source: Allied Minds)

Bristol Meyers-Squibb to Aquire Padlock Therapeutics, Ltd. (Source: Padlock Therapeutics)

Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy (Source: Blueprint Medicines)

Bristol-Myers Squibb and LabCentral Team Up in Cambridge, Massachusetts to Support Promising Biotech Startup Companies (Source: Bristol-Myers Squibb)

Biogen Joins Pioneering Target Validation Collaboration (Source: Biogen)

AstraZeneca Enters Licensing Agreement with China Medical System Holdings for Hypertension Medicine (Source: AstraZeneca)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) (Source: Broad Institute)

Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical Company to Evaluate RAD1901 Combination Regimens in Advanced Breast Cancer (Source: Radius Health)

AstraZeneca and BIND Therapeutics publish AZD2811 ACCURINS® data in Science Translational Medicine (Source: AstraZeneca)

Dana-Farber Cancer Institute’s Belfer Center announces Immuno-Oncology research collaboration with Array BioPharma (Source: Dana Farber Cancer Institute)

Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522 (Source: Takeda Pharmaceuticals)

AstraZeneca and MedImmune enter consortium to deliver new treatments for chronic kidney disease (Source: AstraZeneca)

Quartet Medicine Announces Strategic Partnership with Merck (Source: Quartet Medicine)

Rodin Announces New Equity Financing and R&D Collaboration with Biogen (Source: Rodin Therapeutics)

Shire to Combine with Baxalta, Creating the Global Leader in Rare Diseases (Source: Baxalta)

Tesaro Announces Definitive Agreement for $155 Million Private Placement (Source: Tesaro)

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestle Health Science (Source: Pronutria Biosciences)

Synlogic Secures $40 Million in Series B Financing (Source: Synlogic)

Yumanity Therapeutics Closes $45 Million Series A Financing (Source: Yumanity Therapeutics)

Aquinnah Pharmaceuticals Receives $5 Million Investment from Takeda Pharmaceuticals to Advance New Therapies in ALS (Source: Business Journals)

Spero Therapeutics Announces $30 Million Series B Preferred Financing (Source: Spero Therapeutics)

Pear Therapeutics Closes $20 Million Financing (Source: Pear Therapeutics)

Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9 (Source: Intellia Therapeutics)

Codiak BioSciences Closes $61 Million Series B Financing (Source: PR Newswire)

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares (Source: Editas Medicine)

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics (Source: Tarveda Therapeutics)

Theracos Raises $25M to Take on Big Pharma in Diabetes (Source: FierceBiotech)

5AM Ventures launching stealth (RNA?) startup Homology Medicines with $23M (Source: MedCity News)

Scholar Rock Announces $36 Million Series B Financing (Source: Scholar Rock)

Navitor Pharmaceuticals Announces $33 Million Series B Financing (Source: Navitor Pharmaceuticals)

Partners HealthCare announces new round of Innovation Grants (Source: Partners Healthcare)

FDA Drug Approvals & Designations

Merck Receives FDA Approval of ZEPATIER (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection (Source: Merck)

Upcoming Events

March 31 – April 1, 2016
Boston Marriott Cambridge Hotel, Cambridge
March 31 – April 1, 2016
Royal Sonesta, Cambridge, MA
April 5, 2016
MassBio, Technology Square, Cambridge
April 12, 2016
Merck Research Laboratories, Boston
April 20, 2016
Westin Copley Place, Boston
 
April 25-27, 2016
Westin Copley Place, Boston
 
April 28, 2016
Royal Sonesta, Cambridge
Follow us on TwitterView our profile on LinkedIn

RSDpress April 2016

Introducing WuXi’s Research Service Division

Dear Readers,
I am pleased to announce the establishment of a new WuXi business division, the Research Service Division (RSD), aimed at providing better support to our partners and promoting efficiency and collaboration between WuXi’s business units. RSD combines WuXi’s capability and technology platform in chemistry and biology to provide open access and integrated service for drug discovery and research. The services included in the new RSD are the International Discovery Service Unit (IDSU), Chemistry Service Unit (CSU), Oncology Unit, the Immunology Center, and Biology Unit (which includes HTS, in vitro screening, infectious disease, neurosciences, CV, and metabolism). This new integration will provide closer points of contacts for our partners and discovery teams, streamline the exceptional services offered across our platform, and enhance efficiency and productivity to drug discovery. We will focus on boosting our scientific capabilities and leading technology development to maintain WuXi’s industry leading position in research service. I look forward to continuing to provide outstanding service to our partners through this new initiative and connecting to our broader discovery community through the new RSDpress!
Best regards,
Steve Yang
Breaking RSD News

WuXi Acquires Crelux
WuXi Webinar: Tackling the Number 1 Drug Product Development Problem: Solubility

WuXi’s upcoming live global webcast, “Tackling the # 1 Drug Product Development Problem: Solubility” will take place on Thursday, May 5, 2016 (10AM PST | 1PM EST | 6PM GMT)
 
Our distinguished speakers include:
Mui Cheung, Director, Medicinal Chemistry, GlaxoSmithKline
Manish Gupta, Head of Biopharmaceutics, Platform Technologies & Science, GlaxoSmithKline
Matt Burke, Head of Drug Delivery, Platform Technologies & Science, GlaxoSmithKline
Riccardo Panicucci, Vice President, Pharmaceutical Development Services, WuXi AppTec
Richard Soll, SVP, International Discovery Service Unit, WuXi AppTec (moderator)
Submit your questions in advance for the speakers during registration!
We look forward to welcoming you to this lively discussion.
Innovation That Matters

Placing ‘Early’ Bets in Biotech – A Chat With Andy Schwab, Co-Founder & Managing Partner, 5AM Ventures

Next Generation Immuno-Oncology: Creating a New Pathway to ‘Eat’ Cancer – A Chat with Jonathan MacQuitty, CEO, Forty Seven

Connecting the Global Autism Scientific Community – A Chat With Alan Packer, Senior Scientist, Simons Foundation Autism Research Initiative

Finding Solutions to Rare Diseases through Genomics: An Interview with Hannes Smárason, WuXi NextCODE

How ‘Cool’ Science Translates Into Successful Companies – A Chat with UNITY Biotechnology CEO, Nathaniel David

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Global WuXi Webinar: Pioneering Approaches to Dismantling Cancer

Juno Therapeutics and WuXi Start New Company to Develop Novel Cell-Based Cancer Immunotherapies in China

WuXi Lab Testing Division’s Analytical and Stability Testing Facilities Passed FDA Inspection

WuXi Opens Office in South Korea

WuXi Spring Reception in San Francisco

WuXi Releases New Mobile App for Compounds Sourcing

Huawei and WuXi Join Forces to Create China Precision Medicine Cloud Platform

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologics in EU Clinical Trial

World’s Largest Autism Dataset Goes Online

WuXi NextCODE Becomes the First and Only CAP, CLIA, and California Accredited Sequencing Laboratory in China

WuXi’s STA Subsidiary Opens New Campus in Changzhou

WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia
In This Issue
Industry Beats

Pfizer Taps IBM for Research Collaboration to Transform Parkinson’s Disease Care (Source: Pfizer)Stanford Scientists Resurrect an Abandoned Drug and Find it Effective Against Two Human Viruses in a Lab Dish, with Potential to Fight Many More (Source: Stanford University)

Scientists Distinguish Molecules Most Capable of Fighting Prostate Cancer (Moscow Institute of Physics and Technology)

Aduro Biotech Helps Launch New Immunotherapy, Vaccine Effort (Source: University of California, Berkeley)


TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License Agreement (Source: Tesaro)

Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium (Source: Johnson & Johnson)

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders (Source: Allergan)

GSK and Miltenyi Biotec Establish Cell and Gene Therapy Collaboration (Source: GSK)

Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy (Source: Blueprint Medicines)

Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc. (Source: Bristol-Myers Squibb)

Horizon Discovery Group plc Enters Immuno-Oncology Therapeutic Development and Forms Joint Venture with Centauri Therapeutics Limited (Source: Avvinity)

Johnson & Johnson Innovation Unveils JLABS @ TMC to Help Catalyze Early Stage Research through to Commercialization for Healthcare Solutions in Houston (Source: Johnson & Johnson)

Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing (Source: PR Newswire)

Amal Therapeutics Raises CHF 3 Million in a Series A Financing Round Led by Boehringer Ingelheim Venture Fund (Source: Amal Therapeutics)

Gadeta Closes EUR 7 Million Series A Financing to Advance Novel Cancer Immunotherapies to the Clinic (Source: Yahoo Finance)

ImmunoMet Therapeutics Raises $5.2 million in a Series A Financing (Source: PR Newswire)

FDA Updates

Upcoming Events

May 11-12, 2016
Berlin, Germany
 
May 13-17, 2016
Seattle, WA
 
May 18-19, 2016
Congress 2016
London, U.K.
 
May 19-20, 2016
London, U.K.
 
May 29 – June 1, 2016
Heidelberg, Germany
May 30-June 2, 2016
Montreal, Canada
 
June 1-2, 2016
San Diego, CA
RSD Collaborator Publications

Two Scalable Syntheses of (S)-2-Methylazetidine. (Journal of Organic Chemistry)
In Case You Missed It

Medicinal Chemistry

 

G protein-coupled receptors as targets for anti-diabetic therapeutics. (Nature Review Drug Discovery)

 
 
Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.(Nature Medicine)

 










Synthetic Chemistry

Dual C-F, C-H Functionalization via Photocatalysis: Access to Multifluorinated Biaryls. (Journal of the American Chemical Society) 

Network Analysis Guided Synthesis of Weisaconitine D and Liljestrandinine. (Nature)

Practical Ni-Catalyzed Aryl-Alkyl Cross-Coupling of Secondary Redox-Active Esters. (Journal of the American Chemical Society)

Strain-release amination. (Science)

Aryl Nitriles from Alkynes Using tert-Butyl Nitrite: Metal-Free Approach to C≡C Bond Cleavage. (ACS Organic Letters)

An Improved System for the Aqueous Lipshutz-Negishi Cross-Coupling of Alkyl Halides with Aryl Electrophiles.(Angewandte Chemie)

Access to Difluoromethylated Arenes by Pd-Catalyzed Reaction of Arylboronic Acids with Bromodifluoroacetate. (ACS Organic Letters)

 
Follow us on TwitterView our profile on LinkedIn

ILpress February 2016

WuXi Collaboration with Israeli Partners

The Future of Cancer Therapy: An Interview with Yinon Ben-Neriah, Hebrew University

WuXi News

Dr. Ge Li Receives Executive of the Year Award from SCRIP

Over 1,100 Executives Signed-up for 4th Annual WuXi Global Forum at J.P. Morgan Conference

WuXi Healthcare Ventures Joins Financing Rounds for Twist Bioscience and Syros Pharmaceuticals

WuXi Plans $120 Million Investment in New Integrated Biologics Solution Center to Expedite Biologics Development from Ideas to Clinic

WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

WuXi Healthcare Ventures II Closes with Oversubscription

WuXi Congratulates MSD on Receiving FDA Approval of ZEPATIER™

Congratulations to Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
Perspectives

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-party Collaboration – An Interview with Dr. Jiawen Han, Vice President, WuXi Biologics

Meet IDSU Leadership: An Interview with Tao Guo, VP of Medicinal Chemistry
In This Issue
Industry Beats

TAU links growth factor to development of Alzheimer’s disease (Source: Tel Aviv University)BioLight Reports Positive Second Clinical Study Results for its TeaRx Multi-Assay Test for Dry Eye Syndrome (Source: PR Newswire)Israeli Pharma Firm to Develop Alternative to Viagra (Source: The Times of Israel)Israeli Researchers Develop Novel Method To Treat Aggressive Blood Cancers (Source: No Camels)Breakthrough Israeli Research Improves HIV/AIDS Treatment, Could Lead To Cure (Source: No Camels)CollPlant Reports Positive Interim Trial Results for Vergenix, Indicated for the Treatment of Tendinopathy (Source: CollPlant)Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications (Source: Can-Fite)Compugen Achieves Third Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer (Source: Compugen)

Kamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment (Source: Kamada)

Teva Announces Launch of Generic Ortho Tri-Cyclen® Lo in the United States (Source: Teva Pharmaceuticals)

Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies (Source: Kite Pharma)

BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer (Source: BioLineRx)

Sanara Ventures Cements Teva-Philips Ties (Source: Sanara Ventures)

J&J Backs Israeli Startup in $28M Round for Heart Failure Implant (Source: Fierce Medical Device)

Phillip Morris Invests $20m in Syqe Cannabis Inhaler (Source: iCAN)

Takeda Provides Further Information about its New Business Venture with Teva (Source: Takeda)

Adicet Bio Announces Closing of $51 Million Series A Financing and Acquisition of Applied Immune Technologies (Source: PR Newswire)

CartiHeal Raises $15 Million (Source: PR Newswire)

Insightec Secures $22 Million and Appoints Maurice R. Ferre, MD, as CEO (Source: Insightec)

Israeli Catheter Co Pi-Cardia Raises $10m (Source: Globes)

KAHR Medical Reports Raising $12M At First Closing Of Its Series B Private Equity Financing (Source: KAHR Medical)

Drug Approvals & Designations

Upcoming Events

February 22-23, 2016
Tel Aviv University, Tel Aviv
 
March 9, 2016
Independence Park, Tel Aviv
 
March 29, 2016
The Hebrew University of Jerusalem, Jerusalem
Follow us on TwitterView our profile on LinkedIn

MApress December 2015

WuXi Boston Holiday Party

WuXi Boston celebrated the holidays with clients and colleagues on Tuesday, December 15, at Viale Restaurant in Cambridge. The evening brought out over 100 representatives from the many research institutes and pharma, biotech, and VC companies in the area. Thanks to all attendees who made it a great night filled with inspiring conversation and festive joy to bring in the new year!
WuXi News

WuXi and MedImmune Form Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

Dr. Ge Li Receives Executive of the Year Award from SCRIP

WuXi Global Forum 2016 at J.P. Morgan Conference

WuXi Healthcare Ventures II Closes with Oversubscription

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility

Cancer, Meet the Alamo: San Antonio Enlists WuXi NextCODE to Speed Unparalleled Open-access Cancer Genome Project

Congratulations to Novira Therapeutics for its Acquisition Agreement with Johnson & Johnson
Innovation That Matters

Combating the Hep B Virus: An Interview with George Hartman, Novira Therapeutics
Perspectives

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-party Collaboration – An Interview with Dr. Jiawen Han, VP of WuXi Biologics

Prospects for Cell and Gene Therapy: An Interview with Alan Moore, VP of Strategic Accounts and Cell Manufacturing

Meet IDSU Leadership: An Interview with Tao Guo, VP of Medicinal Chemistry
In This Issue
Industry Beats

Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals (Source: Business Wire)

Avedro Completes New $32 Million Round of Financing (Source: Avedro)

FDA Approvals & Designations

Upcoming Events

January 21, 2016
Mass Bio, 300 Tech Square, Cambridge, MA
January 21-22, 2016
Courtyard Boston Logan Airport Hotel
February 3, 2016
Princeton, MA
February 23-26, 2016
Boston, MA
WuXi AppTec
222 Third Street, Suite 1100
Cambridge, MA 02142
857-242-3984
Follow us on TwitterView our profile on LinkedIn

SDpress December 2015

 

WuXi News

Dr. Ge Li Receives Executive of the Year Award from SCRIP

WuXi and MedImmune Form Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

WuXi Global Forum 2016 at J.P. Morgan Conference

WuXi Healthcare Ventures II Closes with Oversubscription

Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility

Cancer, Meet the Alamo: San Antonio Enlists WuXi NextCODE to Speed Unparalleled Open-access Cancer Genome Project

Congratulations to Novira Therapeutics for its Acquisition Agreement with Johnson & Johnson
Innovation That Matters

Combating the Hep B Virus: An Interview with George Hartman, Novira Therapeutics
Perspectives

Combining Service and Investment: An Interview with Wei Li, Co-Founder of WuXi Healthcare Ventures

Developing a Novel ADC for Global Market via Innovative Three-party Collaboration – An Interview with Dr. Jiawen Han, VP of WuXi Biologics

Prospects for Cell and Gene Therapy: An Interview with Alan Moore, VP of Strategic Accounts and Cell Manufacturing

Meet IDSU Leadership: An Interview with Tao Guo, VP of Medicinal Chemistry
In This Issue:
Industry Beats

FDA Approvals & Designations

Upcoming Events

January 12, 2016
DNC Auditorium
The Scripps Research Institute
 
January 20-22, 2016
Salk Institute
February 24, 2016
The Lodge at Torrey Pines

 

 

IDSUpress December 2015

Meet IDSU Leadership

Meet IDSU Leadership: Tao Guo, Vice President of Medicinal Chemistry

 

IDSU Collaborator Publications

Innovation That Matters

Combatting the Hep B Virus: An Interview with George Hartman, Novira Therapeutics

 

WuXi News

 

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

Congratulations to Novira Therapeutics for its Acquisition Agreement with Johnson & Johnson
In Case You Missed It

Medicinal Chemistry

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. T L Lasho et. al. Blood Cancer Journal 2015 5(e275).

Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis. Colin. A. Flaveny et al. Cancer Cell (2015) 28, pp. 42-56. 

Inhibiting one kinase to kill them all, Leslie K. Ferrarelli. Science Signaling, 2015, 8 (397) pp. ec284.

 

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor Chia-Yung Wu, et. al. Science, 2015, 8 (399), pp. ec300.

Synthetic Chemistry

A fluorinated ligand enables room-temperature and regioselective pd-catalyzed fluorination of aryl triflates and bromides. Aaron C. Sather et. al. Journal of the American Chemical Society, 2015.  

In This Issue
Industry Beats

 

Merck Serono Expands Biopharmaceutical R&D Facility to Accelerate Innovation at Darmstadt Headquarters (Source: EMD Group)

 

FDA Updates

Upcoming Events

December 3, 2015
London, U.K.
December 15-20, 2015
Honolulu, HI
January 20-21, 2016
London, U.K.
February 21-24, 2016
San Diego, CA
February 24-26, 2016
Budapest, Hungary
 
February 29-March 2, 2016
San Diego, CA

 

MApress October 2015

WuXi News

WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan

WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan

WuXi Boston Welcomes Valdas Jurkauskas to Join the STA Team: An Interview with Valdas Jurkauskas, Executive Director, Technical Operations, WuXi STA

WuXi Hosts Symposium in Cambridge: Expediting Your Preclinical Development Timeline with an Integrated CRO

WuXi NextCODE in Bloomberg on Ending a 30-year Diagnostic Odyssey in 3 Weeks

Sidra Selects WuXi NextCODE to Power Population Genomics and Precision Medicine in Qatar

Read full article here

WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China 

WuXi Launches Mobile OncoWuXi, the World’s First App for Accessing Oncology Services

Read full article here

Thirteen New Suppliers Have Joined LabNetwork’s October 2nd Release  

 

Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi Headquarters in Shanghai  
Perspectives

Meet WuXi’s Israeli Partner: An Interview with Ran Nussbaum, Co-Founder and Managing Partner of Pontifax
In This Issue
Industry Beats

FDA Approvals & Designations

Upcoming Events

October 26-29, 2015
Hynes Convention Center, Boston, MA
October 29, 2015
Merck Boston Auditorium, Boston, MA


October 27, 2015
Google’s Cambridge Headquarters, 355 Main Street, Cambridge, MA
November 5, 2015
Online
 
November 9-10, 2015
Seaport World Trade Center, Boston, MA
November 13, 2015
Renaissance Boston Waterfront Hotel, Boston, MA
November 17-18, 2015
Harvard Club, Cambridge, MA

SDpress October 2015

 

WuXi News

Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi Headquarters in Shanghai  

WuXi Receives 2015 Open-Access R&D Technology Leadership Award from Frost & Sullivan

WuXi Receives 2015 Asian CRO Company of the Year Award from Frost & Sullivan

WuXi NextCODE in Bloomberg on Ending a 30-year Diagnostic Odyssey in 3 Weeks

Sidra Selects WuXi NextCODE to Power Population Genomics and Precision Medicine in Qatar

Read full article here

WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China 

WuXi Launches Mobile OncoWuXi, the World’s First App for Accessing Oncology Services

Read full article here

WuXi Launches Medical Device Testing Services in China

Perspectives

An Interview with Valdas Jurkauskas, Executive Director, Technical Operations, WuXi STA

Meet WuXi’s Israeli Partner: An Interview with Ran Nussbaum, Co-Founder and Managing Partner of Pontifax
In This Issue
Industry Beats

FDA Approvals & Designations

Upcoming Events

November 5, 2015
Conrad T. Prebys Auditorium, Salk Institute 
 
November 8, 2015
Salk Institute
 
November 10, 2015
Auditorium at TSRI, The Scripps Research Institute
 
November 17, 2015
Biocom, San Diego
 
December 7-10, 2015
San Diego Convention Center